Compare · NTR vs NXTS
NTR vs NXTS
Side-by-side comparison of Nutrien Ltd. (NTR) and Nexentis Technologies Inc. (NXTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTR and NXTS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- NTR is the larger of the two at $35.11B, about 13057.1x NXTS ($2.7M).
- NTR has been more active in the news (6 items in the past 4 weeks vs 2 for NXTS).
- NTR has more recent analyst coverage (25 ratings vs 0 for NXTS).
- Company
- Nutrien Ltd.
- Nexentis Technologies Inc.
- Price
- $73.19+0.48%
- $1.84-4.17%
- Market cap
- $35.11B
- $2.7M
- 1M return
- +5.36%
- -
- 1Y return
- +24.97%
- -
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 0
NTR
Nutrien Ltd.
Nutrien Ltd. provides crop inputs, services, and solutions. The company offers potash, nitrogen, phosphate, and sulfate products; and financial solutions. It also distributes crop nutrients, crop protection products, seeds, and merchandise products through approximately 2,000 retail locations in the United States, Canada, South America, and Australia. The company was incorporated in 2017 and is headquartered in Saskatoon, Canada.
Latest NTR
- Nutrien downgraded by National Bank Financial with a new price target
- SEC Form SD filed by Nutrien Ltd.
- SEC Form 6-K filed by Nutrien Ltd.
- SEC Form 6-K filed by Nutrien Ltd.
- Nutrien Declares Quarterly Dividend of US$0.55 per Share
- Nutrien Reports Second Quarter 2026 Results
- Nutrien upgraded by BNP Paribas Exane with a new price target
- Nutrien Announces Release Dates for Second Quarter 2026 Results and Conference Call
- Nutrien downgraded by Jefferies with a new price target
- SEC Form 6-K filed by Nutrien Ltd.
Latest NXTS
- SEC Form 10-Q filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form S-1 filed by Nexentis Technologies Inc.
- SEC Form POS AM filed by Nexentis Technologies Inc.
- Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
- Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
- SEC Form 424B5 filed by Nexentis Technologies Inc.